Maraviroc is a novel CCR5 antagonist and is the most advanced clinical candidate in Pfizer's CCR5 discovery and development programme. It is exquisitely selective for the CCR5 receptor and demonstrates potent activity in vitro against both lab-adapted and primary clinical HIV isolates spanning all of the clades, including viruses that are resistant to current classes of HIV agents. Maraviroc has been evaluated in >400 volunteers and in 66 HIV patients where it is well tolerated at doses in excess of those required to block the CCR5 receptor and those providing free drug levels above the in vitro concentrations for potent antiviral activity. Consistent with this, Maraviroc has demonstrated encouraging short-term (10 day), single agent efficacy as measured by reductions in viral loads in asymptomatic HIV patients; doses of 300 mg QD and 300 mg BID resulted in mean maximum HIV RNA reductions of 1.60log 10 and 1.84log 10 , respectively. Studies both with CYP 3A4 inhibitors and inducers have demonstrated that Maraviroc will have manageable drug interactions when used in the setting of HIV patients receiving HAART. In summary, Maraviroc has potency, pharmacokinetic and toleration profiles that merit its further evaluation as a new therapy for patients with HIV/AIDS. [link 'here' using 'a href' to: <url>http://www.biomedcentral.com/content/pdf/1742-4690-2-S1-full.pdf</url>]</note> </supplement>
